Prosecution Insights
Last updated: July 17, 2026

Norton Rose Fulbright US LLP - Chmc

9 pending office actions • 4 clients • 8 examiners • 6 art units • 0 of 9 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Quality Metrics (n=120 apps, methodology: how we score firms)

85.2%
Allowance Rate
n=120
+0.84σ
Allowance Rate (norm)
n=120
5.2
OAs to Allowance
n=23
+0.33σ
OAs to Allow (norm)
n=23
1451 days
Time to Allowance
n=23
+40.0pp
Interview Lift
n=120
96.3%
RCE Rate
n=120
0.0%
Appeal Rate
n=120

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=3 (min 20)
§102 Overcome
n=5 (min 20)
56.2%
§103 Overcome
n=32
§112 Overcome
n=10 (min 20)

Specialization & Scale

C12N, G01N, A61K
Top CPC Subclasses
65%
Top-3 CPC Share
n=120
0
Practitioners
n=120
Apps / Practitioner
n=120 (min 20)

Portfolio Summary

9
Total Pending OAs
5
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (11%)
7
Medium (78%)
1
Easy (11%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (11%)
§103 only6 (67%)
§102 only1 (11%)
§112 only1 (11%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MONTANARI, DAVID A 2 65.0% +49.4%
JACKSON III, WALTER 1
CASH, KAILEY ELIZABETH 1 31.3% +56.7%
MIANO, JOSEPH PAUL 1 36.8% +63.7%
IVICH, FERNANDO NMN 1 45.5% +76.1%
MCLEOD, AFRICA MHAIRIE 1 50.0% +71.9%
BEHARRY, ZANNA MARIA 1 22.7% +50.5%
REGLAS, GILLIAN CHELSEA 1 29.1% +51.5%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17421908 COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER REGLAS, GILLIAN CHELSEA 91d overdue
17634148 METHODS FOR MAKING ORGANOID COMPOSITIONS BEHARRY, ZANNA MARIA

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17421908 COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER REGLAS, GILLIAN CHELSEA 91d overdue
17638753 ORGANOID MESODERM LINEAGE DIVERSIFICATION MONTANARI, DAVID A 34d
18104055 NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS IVICH, FERNANDO NMN 62d
18473619 COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME MONTANARI, DAVID A
18264741 A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK CASH, KAILEY ELIZABETH
18027900 RAFT CULTURES AND METHODS OF MAKING THEREOF MIANO, JOSEPH PAUL
18003130 MODEL FOR INSULIN RESISTANCE MCLEOD, AFRICA MHAIRIE
17634148 METHODS FOR MAKING ORGANOID COMPOSITIONS BEHARRY, ZANNA MARIA

Client Portfolio (4 clients)

Top Art Units

Art UnitApps
16324
16381
16831
16311
16781
16351

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18568764 LIVER ORGANOID MODEL FOR HYPERBILIRUBINEMIA AND METHODS OF MAKING AND USING SAME Children’S Hospital Medical Center JACKSON III, WALTER 1638 §103 Non-Final OA 29d Pending Dec 08, 2023
18473619 COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME Children'S Hospital Medical Center MONTANARI, DAVID A 1632 §103 Non-Final OA Pending Sep 25, 2023
18264741 A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK VANDERBILT UNIVERSITY CASH, KAILEY ELIZABETH 1683 §103 Final Rejection Pending Aug 08, 2023
18027900 RAFT CULTURES AND METHODS OF MAKING THEREOF Children'S Hospital Medical Center MIANO, JOSEPH PAUL 1631 §103 Final Rejection Pending Mar 22, 2023
18104055 NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS Children'S Hospital Medical Center IVICH, FERNANDO NMN 1678 §112 Non-Final OA 62d Pending Jan 31, 2023
18003130 MODEL FOR INSULIN RESISTANCE Children'S Hospital Medical Center MCLEOD, AFRICA MHAIRIE 1635 §103 Final Rejection Pending Dec 22, 2022
17638753 ORGANOID MESODERM LINEAGE DIVERSIFICATION Riken MONTANARI, DAVID A 1632 §102 Final Rejection 34d Pending Feb 25, 2022
17634148 METHODS FOR MAKING ORGANOID COMPOSITIONS Children'S Hospital Medical Center BEHARRY, ZANNA MARIA 1632 §101 Non-Final OA Pending Feb 09, 2022
17421908 COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER Children'S Hospital Medical Center REGLAS, GILLIAN CHELSEA 1632 §103 Non-Final OA 91d overdue Pending Jul 09, 2021

Managing Norton Rose Fulbright US LLP - Chmc's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month